Table 1. Patients, tumor and treatment characteristics.
Characteristic | Value |
---|---|
Age at PCA diagnosis, years | |
Median (range) | 62 (47–75) |
PSA at PCA diagnosis, ng/mL | |
Median (range) | 9.8 (0.54–159) |
PSA at SBRT, ng/mL | |
Median (range) | 1.9 (0.16–59.8) |
Gleason score, N (%) | |
≤6 | 3 (6) |
7 | 28 (56) |
≥8 | 18 (36) |
unknown | 1 (2) |
Primary tumor size (T), N (%) | |
c/pT1-T2b | 16 (32) |
c/pT2c-T3 | 32 (64) |
Tx | 2 (4) |
Regional lymph node involvement at PCA diagnosis, N (%) | |
c/pN0 | 36 (72) |
c/pN1 | 11 (22) |
Nx | 3 (6) |
PCA treatment, N (%) | |
RP | 15 (30) |
RT | 4 (8) |
RP and RT | 31 (62) |
ADT at the time of SBRT, N (%) | |
no | 35 (70) |
yes | 15 (30) |
Time to metastases from diagnosis of PCA (months) | |
Median (range) | 37 (1–199) |
Number of metastases treated at first SBRT, N (%) | |
1 | 35 (70) |
2 | 9 (18) |
3 | 3 (6) |
4 | 2 (4) |
5 | 1 (2) |
Primary site of metastases, N (%) | |
Lymph node | 24 (48) |
Pelvic | 15 (62.5) |
Extra-pelvic | 8 (33.3) |
Both | 1 (4.2) |
Bone | 23 (46) |
Bone and lymph node | 2 (4) |
Lung | 1 (2) |
Maximal SUV of PSMA-PET/CT | |
Median (range) | 6 (2.6–42) |
Fractionation schedules, N (%) | |
SFRS | 60 (80) |
3 fractions | 13 (17.3) |
other | 2 (2.7) |
Median dose (Gy) for SFRS (range) | 20 (16–25) |
Median dose (Gy) for fSBRT(range) | 24 (19.2–28.8) |
Abbreviations: ADT = androgen deprivation therapy; fSBRT = fractionated stereotactic body radiotherapy; PCA = prostate cancer; PSA = prostate-specific antigen; PSMA-PET/CT = prostate-specific membrane antigen positron emission tomography/computed tomography; RP = radical prostatectomy; RT = radiotherapy; SBRT = stereotactic body radiotherapy; SFRS = single fraction radiosurgery; SUV = standardized uptake value.